![Min-Chul Park](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Min-Chul Park
Directeur/Membre du Conseil chez ZYVERSA THERAPEUTICS, INC.
Fortune : - $ au 30/06/2024
Postes actifs de Min-Chul Park
Sociétés | Poste | Début | Fin |
---|---|---|---|
ZYVERSA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/12/2022 | - |
Independent Dir/Board Member | 01/12/2022 | - | |
ZyVersa Therapeutics Operating, Inc.
![]() ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Directeur/Membre du Conseil | - | - |
Inje University | Corporate Officer/Principal | - | - |
Historique de carrière de Min-Chul Park
Anciens postes connus de Min-Chul Park
Sociétés | Poste | Début | Fin |
---|---|---|---|
CURE BIO Co., Ltd.
![]() CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Directeur/Membre du Conseil | 01/10/2020 | 01/04/2022 |
Directeur Général | 01/10/2020 | 01/04/2022 | |
Neomics Co., Ltd.
![]() Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Directeur/Membre du Conseil | - | - |
Directeur Général | - | - |
Formation de Min-Chul Park
Seoul National University | Doctorate Degree |
Statistiques
Internationale
Corée du Sud | 5 |
Etats-Unis | 3 |
Opérationnelle
Director/Board Member | 5 |
Chief Executive Officer | 3 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ZYVERSA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Neomics Co., Ltd.
![]() Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Health Technology |
ZyVersa Therapeutics Operating, Inc.
![]() ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Health Technology |
CURE BIO Co., Ltd.
![]() CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Health Technology |
- Bourse
- Insiders
- Min-Chul Park
- Expérience